An interventional study of Arthroscopic Rotator Cuff Repair and Autologous Fibrin Clot in Rotator Cuff Tears and Rotator Cuff Injuries, sponsored by Ataturk University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Ataturk University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Rotator Cuff Injuries with a site in Turkey — 19 open to participants now, 22 under way, none of them phase 3. Rotator Cuff Injuries · Turkey.
Among the 85 studies in Rotator Cuff Injuries with a site in Turkey, this one is the 24th largest by enrollment of the 63 interventional ones that give a count, is one of 12 that started in 2025, is one of 63 with no phase, reaches primary completion later than 19 of the 21 other live ones, and was the 85th registered.
632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.
Browse Rotator Cuff Injuries studies →19 of the 85 studies in Rotator Cuff Injuries with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul Medeniyet University · Sites in Turkey
Ages 18+ · Healthy volunteers
Firat University · Sites in Turkey
Ages 18–65
Ahi Evran University Education and Research Hospital · Sites in Turkey
Ages 40–60
Istanbul Nisantasi University · Sites in Turkey
Ages 18–75
Balikesir Ataturk City Hospital · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 60 across 456 interventional studies indexed under Rotator Cuff Injuries.
Median enrollment 44 across the 63 interventional studies, 50 across the 22 observational. Of the 58 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 85 has an industry lead sponsor. The 10 most frequent:
Ataturk University is the lead sponsor of 463 studies on the registry; 123 are open to participants now.
Ataturk University has 1 study filed under Rotator Cuff Injuries — fewer than ten, so there is no comparison to draw.
3 of the studies in Rotator Cuff Injuries with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07377292Ahi Evran University Education and Research HospitalEffectiveness of Core Stabilization Exercises in Rotator Cuff Injuries | 2026-12-25 |
| NCT07853950Ataturk UniversityFibrin Clot Augmentation in Arthroscopic Rotator Cuff Repair | 2027-02-28 |
| NCT07428070Istanbul Nisantasi UniversityContextually Enhanced Exercise Programs for Rotator Cuff-Related Shoulder Pain | 2027-05-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 85 studies in Rotator Cuff Injuries with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate whether applying an autologous fibrin clot to the repair site improves tendon healing and clinical outcomes after arthroscopic rotator cuff repair. Fifty patients with rotator cuff tears requiring surgery were randomly assigned to two groups: arthroscopic repair with autologous fibrin clot augmentation or standard arthroscopic repair alone. The fibrin clot is prepared from the patient's own blood without centrifugation. Tendon healing is assessed with magnetic resonance imaging (MRI) using the Sugaya classification at 12 months, and shoulder function and pain are assessed with the ASES score, Constant score and Visual Analog Scale (VAS) preoperatively and at 3, 6 and 12 months.
Rotator cuff tears are a common cause of shoulder pain and dysfunction, and retear after surgical repair remains a significant problem. Biological augmentation strategies aim to enhance healing at the tendon-bone interface. Autologous fibrin clot is a simple, low-cost biological augment that provides a fibrin scaffold containing platelets and growth factors, and it can be prepared intraoperatively without centrifugation or commercial kits.
In this prospective, randomized, double-blind controlled trial, 50 patients aged 18-80 years with full-thickness or partial-thickness rotator cuff tears (Goutallier fatty infiltration grade 1 or 2) and an indication for surgical repair were randomly allocated in a 1:1 ratio using a computer-generated randomization sequence to either the fibrin clot group (n=25) or the control group (n=25). Patients and outcome assessors are blinded to group allocation.
In the fibrin clot group, 40 mL of venous blood is drawn from the patient during surgery and stirred with a sterile glass rod until a fibrin clot forms. The clot is then delivered arthroscopically to the tendon-bone repair interface. The control group undergoes the same arthroscopic rotator cuff repair without fibrin clot application. Both groups follow the same postoperative rehabilitation protocol.
The primary outcome is rotator cuff repair integrity evaluated with MRI according to the Sugaya classification at 12 months postoperatively. Secondary outcomes are ASES score, Constant score and VAS pain score, assessed preoperatively and at 3, 6 and 12 months postoperatively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arthroscopic rotator cuff repair augmented with an autologous fibrin clot applied to the tendon-bone repair interface.
Procedure: Arthroscopic Rotator Cuff Repair · Biological: Autologous Fibrin Clot
Standard arthroscopic rotator cuff repair without fibrin clot augmentation.
Procedure: Arthroscopic Rotator Cuff Repair
Standard arthroscopic repair of the torn rotator cuff tendon to its footprint using suture anchors.
40 mL of venous blood is drawn from the patient during surgery and stirred with a sterile glass rod until a fibrin clot forms, without centrifugation. The clot is delivered arthroscopically to the tendon-bone repair interface.
Also known as: Endogenous Fibrin Clot
Rotator Cuff Repair Integrity on MRI (Sugaya Classification)
Repair integrity is evaluated with magnetic resonance imaging and classified according to the Sugaya classification (Type I to V). Types I-III are considered healed and Types IV-V are considered retear. The proportion of healed repairs and the retear rate are compared between groups.
Time frame: 12 months postoperatively
American Shoulder and Elbow Surgeons (ASES) Score
Patient-reported shoulder pain and function score ranging from 0 to 100, with higher scores indicating better shoulder function.
Time frame: Preoperatively and at 3, 6 and 12 months postoperatively
Constant-Murley Score
Shoulder function score including pain, activities of daily living, range of motion and strength, ranging from 0 to 100, with higher scores indicating better shoulder function.
Time frame: Preoperatively and at 3, 6 and 12 months postoperatively
Visual Analog Scale (VAS) for Pain
Shoulder pain intensity measured on a 0-10 scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
Time frame: Preoperatively and at 3, 6 and 12 months postoperatively
Plan to share: No — Individual participant data will not be publicly shared due to patient confidentiality. De-identified data may be made available by the principal investigator upon reasonable request.
Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.
Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 15 months is below that.
Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.